Figure 2

EZH2 and BMI1 inversely correlate with variables associated with survival. (a) EZH2 and BMI1 distribution differ by grade. Mean EZH2 mRNA levels are -0.62 (n = 75), -0.21 (n = 101) and 0.37 (n = 119) for grades 1, 2 and 3, respectively (p < 0.0001 Kruskal-Wallis test). Mean BMI1 mRNA levels are 0.0067, -0.15 and -0.41 for grades 1, 2 and 3, respectively (p = 0.0001 Kruskal-Wallis test). (b) EZH2 and BMI1 distribution differ by oestrogen receptor (ER) status. Tumours are regarded ER-positive when more than 10% of the tumour cells stain positive for ER immunohistochemistry and ER-negative otherwise. Mean EZH2 levels are 0.34 for ER-negative (n = 81) tumours and -0.27 for ER-positive (n = 214) tumours (p < 0.0001 Wilcoxon test). Mean BMI1 levels are -0.56 for ER-negative and -0.08 for ER-positive tumours (p < 0.0001 Wilcoxon test). (c) EZH2 and BMI1 distribution differ by 70-gene profile. Mean EZH2 levels are -0.58 for tumours with a good prognosis signature (n = 115) and 0.22 for tumours with a poor prognosis signature (n = 180) (p < 0.0001 Wilcoxon test). Mean BMI1 levels are -0.005 for good prognosis tumours and -0.35 for poor prognosis tumours (p < 0.0001 Wilcoxon test).